Search

Displaying 81 - 90 of 13325
Drupal spam blocked by CleanTalk.
Author year
The incidence of invasive fungal infections in children, adolescents and young adults with acute lymphoblastic leukaemia/lymphoma treated with the UKALL2011 protocol: a multicentre retrospective study. O'Reilly MA, Govender D, Kirkwood AA, Vora A, Samarasinghe S, Khwaja A, Grandage V, Rao A, Ancliff P, Pavasovic V, Cheng D, Carpenter B, Daw S, Hough R, O'Connor D. 2019
A clinical pharmacist survey of prophylactic strategies used to prevent adverse events of lipid-associated formulations of amphotericin B. Chastain DB, Giles RL, Bland CM, Franco-Paredes C, Henao-Martínez AF, Young HN. 2019
Determination of Azole Resistance and TR34/L98H Mutations in Isolates of Aspergillus Section Fumigati from Turkish Cystic Fibrosis Patients. Güngör Ö, Sampaio-Maia B, Amorim A, Araujo R, Erturan Z. 2019
Neutropenic Enterocolitis in Critically Ill Patients: Spectrum of the Disease and Risk of Invasive Fungal Disease. Duceau B, Picard M, Pirracchio R, Wanquet A, Pène F, Merceron S, Mokart D, Moreau AS, Lengliné E, Canet E, Lemiale V, Mariotte E, Azoulay E, Zafrani L. 2019
Reinvestigation of carbohydrate specificity of EB-A2 monoclonal antibody used in the immune detection of Aspergillus fumigatus galactomannan. Krylov VB, Solovev AS, Argunov DA, Latgé JP, Nifantiev NE. 2019
One year prospective survey of azole resistance in Aspergillus fumigatus at a French cystic fibrosis reference centre: prevalence and mechanisms of resistance R -A Lavergne, F Morio, I Danner-Boucher, D Horeau-Langlard, V David, F Hagen, J F Meis, P Le Pape 2019
Translational medical mycology guides clinical and laboratory practice on fungal diseases Lama J, Ran YP, Ran X. 2014
Unravelling species boundaries in the Aspergillus viridinutans complex (section Fumigati): opportunistic human and animal pathogens capable of interspecific hybridization. Hubka V, Barrs V, Dudová Z, Sklenář F, Kubátová A, Matsuzawa T, Yaguchi T, Horie Y, Nováková A, Frisvad JC, Talbot JJ, Kolařík M. 2019
High voriconazole target-site exposure after approved sequence dosing due to nonlinear pharmacokinetics assessed by long-term microdialysis. Kirbs C, Kluwe F, Drescher F, Lackner E, Matzneller P, Weiss J, Zeitlinger M, Kloft C. 2019
Novel insights into P450 BM3 interactions with FDA-approved antifungal azole drugs. Jeffreys LN, Poddar H, Golovanova M, Levy CW, Girvan HM, McLean KJ, Voice MW, Leys D, Munro AW. 2019

Pages

Subscribe to Search